Diagnosis and Management of Rheumatoid Arthritis von Wasserman, Amy M., MD

Volltext

Cognitive Function in a Randomized Trial of Evolocumab von Giugliano, Robert P, Mach, François, Zavitz, Kenton, Kurtz, Christopher, Im, Kyungah, Kanevsky, Estella, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S, Sever, Peter S, Robinson, Jennifer G, Honarpour, Narimon, Wasserman, Scott M, Ott, Brian R

Volltext

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events von Sabatine, Marc S, Giugliano, Robert P, Wiviott, Stephen D, Raal, Frederick J, Blom, Dirk J, Robinson, Jennifer, Ballantyne, Christie M, Somaratne, Ransi, Legg, Jason, Wasserman, Scott M, Scott, Robert, Koren, Michael J, Stein, Evan A

Volltext

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia von Stein, Evan A, Honarpour, Narimon, Wasserman, Scott M, Xu, Feng, Scott, Rob, Raal, Frederick J

Volltext

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial von Raal, Frederick J, Prof, Honarpour, Narimon, MD, Blom, Dirk J, MD, Hovingh, G Kees, MD, Xu, Feng, MS, Scott, Rob, MD, Wasserman, Scott M, MD, Stein, Evan A, Prof

Volltext

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk von Kiyosue, Arihiro, MD, PhD, Honarpour, Narimon, MD, PhD, Kurtz, Christopher, MD, Xue, Allen, PhD, Wasserman, Scott M., MD, Hirayama, Atsushi, MD, PhD

Volltext

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) von Raal, Frederick J., MB BCh, MMed, PhD, Giugliano, Robert P., MD, SM, Sabatine, Marc S., MD, MPH, Koren, Michael J., MD, Langslet, Gisle, MD, Bays, Harold, MD, Blom, Dirk, PhD, MD, Eriksson, Mats, MD, Dent, Ricardo, MD, Wasserman, Scott M., MD, Huang, Fannie, MS, Xue, Allen, PhD, Albizem, Moetaz, MD, Scott, Rob, MD, Stein, Evan A., MD, PhD

Volltext

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia von Blom, Dirk J, Hala, Tomas, Bolognese, Michael, Lillestol, Michael J, Toth, Phillip D, Burgess, Lesley, Ceska, Richard, Roth, Eli, Koren, Michael J, Ballantyne, Christie M, Monsalvo, Maria Laura, Tsirtsonis, Kate, Kim, Jae B, Scott, Rob, Wasserman, Scott M, Stein, Evan A

Volltext

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance von Stroes, Erik, MD, PhD, Colquhoun, David, MD, Sullivan, David, MD, Civeira, Fernando, MD, Rosenson, Robert S., MD, Watts, Gerald F., DSc, PhD, DM, Bruckert, Eric, MD, Cho, Leslie, MD, Dent, Ricardo, MD, Knusel, Beat, PhD, Xue, Allen, PhD, Scott, Rob, MD, Wasserman, Scott M., MD, Rocco, Michael, MD

Volltext

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial von Raal, Frederick J, Prof, Stein, Evan A, Prof, Dufour, Robert, MD, Turner, Traci, MD, Civeira, Fernando, MD, Burgess, Lesley, Prof, Langslet, Gisle, MD, Scott, Russell, Prof, Olsson, Anders G, Prof, Sullivan, David, MD, Hovingh, G Kees, MD, Cariou, Bertrand, MD, Gouni-Berthold, Ioanna, MD, Somaratne, Ransi, MD, Bridges, Ian, MSc, Scott, Rob, MD, Wasserman, Scott M, MD, Gaudet, Daniel, Prof

Volltext

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial von Charytan, David M, Sabatine, Marc S, Pedersen, Terje R, Im, KyungAh, Park, Jeong-Gun, Pineda, Armando Lira, Wasserman, Scott M, Deedwania, Prakash, Olsson, Anders G, Sever, Peter S, Keech, Anthony C, Giugliano, Robert P

Volltext

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a rando... von Koren, Michael J, Dr, Scott, Rob, MD, Kim, Jae B, MD, Knusel, Beat, PhD, Liu, Thomas, PhD, Lei, Lei, PhD, Bolognese, Michael, MD, Wasserman, Scott M, MD

Volltext

Effect of Evolocumab on Coronary Plaque Composition von Nicholls, Stephen J., Puri, Rishi, Anderson, Todd, Ballantyne, Christie M., Cho, Leslie, Kastelein, John J.P., Koenig, Wolfgang, Somaratne, Ransi, Kassahun, Helina, Yang, Jingyuan, Wasserman, Scott M., Honda, Satoshi, Shishikura, Daisuke, Scherer, Daniel J., Borgman, Marilyn, Brennan, Danielle M., Wolski, Kathy, Nissen, Steven E.

Volltext

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359... von Stein, Evan A, Giugliano, Robert P, Koren, Michael J, Raal, Frederick J, Roth, Eli M, Weiss, Robert, Sullivan, David, Wasserman, Scott M, Somaratne, Ransi, Kim, Jae B, Yang, Jingyuan, Liu, Thomas, Albizem, Moetaz, Scott, Rob, Sabatine, Marc S

Volltext

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2... von Cleland, John GF, Prof, Teerlink, John R, Prof, Senior, Roxy, Prof, Nifontov, Evgeny M, Prof, Mc Murray, John JV, Prof, Lang, Chim C, Prof, Tsyrlin, Vitaly A, Prof, Greenberg, Barry H, Prof, Mayet, Jamil, MD, Francis, Darrel P, MD, Shaburishvili, Tamaz, MD, Monaghan, Mark, PhD, Saltzberg, Mitchell, MD, Neyses, Ludwig, Prof, Wasserman, Scott M, MD, Lee, Jacqueline H, Saikali, Khalil G, PhD, Clarke, Cyril P, MBBS, Goldman, Jonathan H, MD, Wolff, Andrew A, MD, Malik, Fady I, MD

Volltext

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial von Sabatine, Marc S., MD, MPH, Giugliano, Robert P., MD, SM, Keech, Anthony, MD, Honarpour, Narimon, MD, PhD, Wang, Huei, PhD, Liu, Thomas, PhD, Wasserman, Scott M., MD, Scott, Robert, MD, Sever, Peter S., MD, Pedersen, Terje R., MD

Volltext

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor von Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.

Volltext

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S] von Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

Volltext

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LA... von Giugliano, Robert P, Dr, Desai, Nihar R, MD, Kohli, Payal, MD, Rogers, William J, Prof, Somaratne, Ransi, MD, Huang, Fannie, MS, Liu, Thomas, PhD, Mohanavelu, Satishkumar, MS, Hoffman, Elaine B, PhD, McDonald, Shannon T, BSN, Abrahamsen, Timothy E, BA, Wasserman, Scott M, MD, Scott, Robert, MD, Sabatine, Marc S, MD

Volltext

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset ana... von Raal, Frederick J, Prof, Hovingh, G Kees, PhD, Blom, Dirk, MD, Santos, Raul D, Prof, Harada-Shiba, Mariko, Prof, Bruckert, Eric, Prof, Couture, Patrick, MD, Soran, Handrean, Prof, Watts, Gerald F, Prof, Kurtz, Christopher, MD, Honarpour, Narimon, MD, Tang, Lihua, PhD, Kasichayanula, Sree, PhD, Wasserman, Scott M, MD, Stein, Evan A, Prof

Volltext